MX2021012406A - Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1. - Google Patents

Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1.

Info

Publication number
MX2021012406A
MX2021012406A MX2021012406A MX2021012406A MX2021012406A MX 2021012406 A MX2021012406 A MX 2021012406A MX 2021012406 A MX2021012406 A MX 2021012406A MX 2021012406 A MX2021012406 A MX 2021012406A MX 2021012406 A MX2021012406 A MX 2021012406A
Authority
MX
Mexico
Prior art keywords
ildr2
antagonists
antibodies
antibody
combination
Prior art date
Application number
MX2021012406A
Other languages
English (en)
Inventor
Ofer Levy
Lars Röse
Uwe Gritzan
Ilan Vaknin
Spencer Liang
John Hunter
Andrew Pow
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2021012406A publication Critical patent/MX2021012406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a un anticuerpo anti-ILDR2, un fragmento o derivado del mismo, un formato de anticuerpo modificado, o un mimético de anticuerpo para utilizar en combinación con un antagonista de PD-1 en el tratamiento de un cáncer. Otros aspectos de la presente invención se relacionan con una combinación que comprende un anticuerpo anti-ILDR2 y un antagonista de PD-1 y el uso de ese tipo de combinación como un medicamento, así como también métodos de tratamiento o profilaxis de un cáncer en un sujeto, que comprende la administración a dicho sujeto de una cantidad terapéuticamente eficaz de los anticuerpos según lo descrito en la presente invención. Adicionalmente, la presente invención se refiere a un kit que comprende anticuerpos anti-ILDR2 y antagonistas de PD-1 y opcionalmente uno o varios otros agentes farmacéuticos.
MX2021012406A 2019-04-11 2020-04-06 Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1. MX2021012406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832320P 2019-04-11 2019-04-11
PCT/EP2020/059745 WO2020207961A1 (en) 2019-04-11 2020-04-06 Combinations of anti-ildr2 antibodies and pd-1 antagonists

Publications (1)

Publication Number Publication Date
MX2021012406A true MX2021012406A (es) 2022-01-19

Family

ID=70224379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012406A MX2021012406A (es) 2019-04-11 2020-04-06 Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1.

Country Status (14)

Country Link
US (1) US20220169736A1 (es)
EP (1) EP3952910A1 (es)
JP (1) JP2022528472A (es)
KR (1) KR20210151808A (es)
CN (1) CN113645999A (es)
AR (1) AR118621A1 (es)
AU (1) AU2020271352A1 (es)
CA (1) CA3136510A1 (es)
IL (1) IL287093A (es)
MX (1) MX2021012406A (es)
PE (1) PE20212271A1 (es)
SG (1) SG11202109623WA (es)
TW (1) TW202104275A (es)
WO (1) WO2020207961A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US8415455B2 (en) 2007-09-04 2013-04-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2013216320A1 (en) * 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US11655297B2 (en) * 2017-11-30 2023-05-23 Bayer Aktiengesellschaft ILDR2 antagonists and combinations thereof

Also Published As

Publication number Publication date
IL287093A (en) 2021-12-01
EP3952910A1 (en) 2022-02-16
SG11202109623WA (en) 2021-10-28
KR20210151808A (ko) 2021-12-14
WO2020207961A1 (en) 2020-10-15
AR118621A1 (es) 2021-10-20
CA3136510A1 (en) 2020-10-15
TW202104275A (zh) 2021-02-01
AU2020271352A8 (en) 2022-04-07
US20220169736A1 (en) 2022-06-02
CN113645999A (zh) 2021-11-12
JP2022528472A (ja) 2022-06-10
PE20212271A1 (es) 2021-11-30
AU2020271352A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
EA201792451A1 (ru) Антитела к ox40 и способы их применения
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
MX2018010546A (es) Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
PH12019501087A1 (en) A pharmaceutical composition for averting opioid addiction
MX2021012406A (es) Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
MX2021004603A (es) Dosificacion.
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
PH12021550529A1 (en) Medicinal composition containing monoclonal antibody or antibody fab fragment thereof, and use thereof